Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive
bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have
received adjuvant chemotherapy).